Other
Issuance of convertible note for accounts payable
Year-over-year, this metric declined by 100.0%, from $62.50K to $0.00. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ1 2024
Last reportedQ4 2025Mar 30, 2026
How to read this metric
An increase suggests the company is prioritizing cash preservation over equity dilution, which may signal liquidity pressure or a strategic choice to extend the cash runway.
Detailed definition
This metric tracks the non-cash settlement of trade payables through the issuance of convertible debt instruments. By co...
Peer comparison
Frequently observed in pre-revenue or growth-stage biopharmaceutical companies that utilize debt-for-equity or debt-for-liability swaps to manage cash burn.
Metric ID:
other_issuance_of_convertible_notes_payable_for_accounts_8e100fHistorical Data
2 years
| FY'24 | FY'25 | |
|---|---|---|
| Value | $250.00K | $0.00 |
| YoY Change | — | -100.0% |
Range$0.00 – $250.00K
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Issuance of convertible note for accounts payable at Other Companies
Frequently Asked Questions
- What is Veradermics 's issuance of convertible note for accounts payable?
- Veradermics (MANE) reported issuance of convertible note for accounts payable of $0.00 in Q4 2025.
- How has Veradermics 's issuance of convertible note for accounts payable changed year-over-year?
- Veradermics 's issuance of convertible note for accounts payable decreased by 100.0% year-over-year, from $62.50K to $0.00.
- What does issuance of convertible note for accounts payable mean?
- The settlement of unpaid bills by issuing convertible debt instead of paying cash.